For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Cagrilintide

Also known as: NN9838

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.

Where to buy · live market data

Who's worth your money for Cagrilintide

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 13 scored sellers

$5.70/mg

$56.99 · 10mg · 99.9% purity

6 COAs
Buy code MERIT · 10% off

Best value

Lowest $/mg among scored sellers

$2.00/mg

$10.00 · 5mg

no COAs yet

Most tested

8 independent COAs on file

$13.50/mg

$135 · 10mg · 99.3% purity

Average price

$13.63/mg

Sellers

66

45-day trend

-2.6%

53 of 66 sellers have a current price· 23 stale hidden· 17 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Cagrilintide

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Cagrilintide

CAS

1415456-99-3

Molecular formula

C194H312N54O59S2

Sequence

KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP

Typical dose range

0.3–4.5 mg once weekly subcutaneous (Phase 2); 2.4 mg/week maintenance in Phase 3 REDEFINE/REIMAGINE trials

Half-life

~159–195 hours (~7–8 days)

Independent evidence

COAs for Cagrilintide

120 third-party tests across 24 vendors. Each card links to the full report.

All 120 COAs for Cagrilintide →
Measured purity 99.0%–100.0% across 80 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG1006162026-02

Aggregated · 3rd-party listing
99.45 %
Jul 2026
ILS Labs Strong

For

Cagrilintide

by Ion Peptide· batch CGL5-06172026

✓ Vendor-published
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Cagrilintide 10

by EZ Peptides· batch EZP-CAG10061620226-02

COA on file
Aggregated · 3rd-party listing
99.79 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Ion Peptide· batch CGL10-06252026

Aggregated · 3rd-party listing
99.56 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Ion Peptide· batch CGL5-06242026

Aggregated · 3rd-party listing
99.93 %
Jun 2026
Janoshik Analytical Limited

For

Cagrilintide

by Optima Supply· batch OS-2026-2806

Aggregated · 3rd-party listing
99.93 %
Jun 2026
Janoshik Analytical Limited

For

Cagrilintide

by Hydro Research Peptides· batch HR-2026-3852

Aggregated · 3rd-party listing
99.87 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0505152026-12

✓ Vendor-published
99.89 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0505152026-12

COA on file
✓ Vendor-published
99.89 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide 5mg

by EZ Peptides· batch EZP-CAG05051520226-12

COA on file
Aggregated · 3rd-party listing
99.93 %
May 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Nox Amino· batch NA-CG0526-01

✓ Vendor-published
99.73 %
May 2026
TrustPointe Analytics Moderate

For

Cagrilintide

by Peptide Partners· batch SPL-3792

COA on file
Aggregated · 3rd-party listing
99.85 %
May 2026
ILS Labs Strong

For

Cagrilintide

by NG Peptide· batch CG10-12

Aggregated · 3rd-party listing
99.35 %
May 2026
ILS Labs Strong

For

Cagrilintide

by NG Peptide· batch CG05-08

Aggregated · 3rd-party listing
99.69 %
Apr 2026
ILS Labs Strong · HPLC

For

Cagrilintide

by Crush Research· batch CRCAG-5-2604-1

✓ Vendor-published
99.91 %
Apr 2026
Kovera Labs

For

Cagrilintide

by Peptide Partners· batch CG202603

COA on file
Aggregated · 3rd-party listing
99.88 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Cagrilintide

by Qihang Peptide· batch 4

Aggregated · 3rd-party listing
99.60 %
Apr 2026
Biogenica Labs · HPLC

For

Cagrilintide

by Amino Club· batch CAG0001

Aggregated · 3rd-party listing
99.90 %
Mar 2026
Kovera Labs

For

Cagrilintide

by Glacier Aminos· batch CAG5GA-02

Aggregated · 3rd-party listing
99.88 %
Mar 2026
Kovera Labs

For

Cagrilintide

by Ion Peptide· batch CAC10-03192026

✓ Vendor-published
99.88 %
Mar 2026
Kovera Labs

For

Cagrliintide

by Ion Peptide· batch CAG10-03192026

COA on file
Aggregated · 3rd-party listing
99.95 %
Mar 2026
Kovera Labs · HPLC

For

Cagrilintide

by Mile High Compounds· batch CAG-010-MH-02

Aggregated · 3rd-party listing
99.18 %
Mar 2026
Vanguard Laboratory Strong

For

Cagrilintide

by Licensed Peptides· batch 032520261

Aggregated · 3rd-party listing
99.28 %
Mar 2026
Horizon Analytical

For

Cagrilintide

by Pepsgpt· batch P-1457978-P

Research depth

20 citations indexed for Cagrilintide

All research on Cagrilintide →

cohort · 2026

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials

Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.

rct · 2026

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.

rct · 2026

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Background Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia.

rct · 2026

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide

Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.

rct · 2026

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

Background The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight.

review · 2026

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis

Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.